Experimental study of the effect of adipose stromal vascular fraction cells on the survival rate of fat transplantation

Objective To investigate the effect of adipose stromal vascular fraction cells(SVFs)on the survival rate of fat ransplantation.Methods 0.5mL autologous fat tissue was mixed with: ① DiI-labeled autologous SVFs (Group A);②

Liver transplantation for hepatocellular carcinoma： is zero recurrence theoretically possible？

BACKGROUND： Hepatocellular carcinoma（HCC） recurrence remains a key issue after liver transplantation. This study aimed to determine a subgroup of HCC patients within the Milan criteria who could achieve a theoretical goal of zero recurrence rates after liver transplantation.METHODS： Between 1999 and 2009, 179 patients who received liver transplantation for HCC within the Milan criteria were retrospectively included. Analysis of the factors associated with HCC recurrence was performed to determine the subgroup of patients at the lowest risk of recurrence.RESULTS： Seventy-two percent of the patients received a bridging therapy, including 54 liver resections. Eleven（6.1%） patients recurred within a delay of 19±22 months and ultimately died. Factors associated with recurrence were serum alpha-fetoprotein level 〉400 ng/m L, satellite nodules, poor differentiation, microvascular invasion and cholangiocarcinoma component. Recurrence rates decreased from 6.1% to 3.1% in patients without any of these factors.CONCLUSIONS： Among HCC patients within the Milan criteria, selecting patients with factors based on histology would allow tending towards zero recurrence, and prior histological assessment by liver biopsy or resection may be essential to rule out poorly differentiated tumors, microvascular invasion,and cholangiocarcinoma component.

Patients 60 Years of Age and Older Should Have the Same Chance for Heart Transplantation or Not?

Heart transplantation is considered the best treatment modality for advanced heart disease. While old age has conventionally been considered a contraindication for heart transplantation due to the reported adverse effect of advanced age, however donor hearts＇ shortage continues to stimulate the discussion about the recipient＇s upper age limit. Our study was based on a retrospective analysis for the results of 52（18%） patients aged 60 years and older undergoing heart transplantation between May 2008 and December 2015, and these patients were compared with 236（82%） adult recipients who were younger than 60 years at the time of transplantation and during the same period. In older group, 71% were males with the mean age of 63.38±3.55 years, and in younger group, 83.4% were males with a mean age of 43.72±11.41 years（P=0.27）. Dilated cardiomyopathy was the most common indication for transplantation among patients in both groups（P=0.147）. In older group, the 3-month survival rate was higher than that in younger group（P=0.587）, however the 6-month survival rate showed no significant difference（P=0.225）. Although the 1-year survival rate was higher in older group（P=0.56）, yet the 3-year survival rate between the two groups showed no statistically significant difference（P=0.48）. According to our experience among older heart transplant candidates who were 60 years and older, we believe that advanced age should not be an excluding criterion to cardiac transplantation.

CARIDIAC TRANSPLANTATION IN PATIENTS OVER 60 YEARS OLD

Objective To reevaluate the age limit for heart transplantation ( HTX) and the long-term outcomes in el derly patients. Methods From Oct. 1984 to Dec. 1996, 161 cases of HTX were performed in Hartford Hospital, with 35 pa tients aged 60～68 years (mean: 63.5±2.7, group A) and 126 under 60 years (mean: 47.6±11.3, group B). The causes of HTX for group A and group B were ischemic : 60% vs 48%, idiopathic: 29% vs 45%, valvular: 6% vs 4 %, congenital: 0 vs 2%, and graft failure : 6 % vs1% . Results The operative mortality (within 30d) were5.7%(2/35) in group A , and1. 6% (2/126) in group B. The overall late death were 13 (37%) in group A, and 50(40% ) in group B. The main causes of dea th were ( group A vs group B) infection: 46 % vs 24 %, rejection: 0 vs 28 % (P<0.05), malignancy: 23 % vs 8 %, multi-or gan system failure:23% vs 2%, cardiac events:8% vs 10%. The 1-,3-,5- ,8- and 10- year survival rate in group A and group B was 74% vs 88%, 67% vs 77%, 60% vs 65%, 49% vs 43%, and 49% vs 34% respectively. The quality of life for both groups was improved remarkably. Conclusion The survival rate for patients over 60 is as good as that of the younger group. HTX could be successfully performed in patients around 65 years old.